Perspective Therapeutics (NYSE:CATX) Stock Rating Upgraded by Lifesci Capital

Lifesci Capital upgraded shares of Perspective Therapeutics (NYSE:CATX) to a strong-buy rating in a report published on Thursday,Zacks.com reports.

Other equities research analysts also recently issued reports about the company. Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Oppenheimer decreased their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Scotiabank started coverage on Perspective Therapeutics in a research report on Friday. They set a “sector outperform” rating and a $15.00 target price on the stock. Finally, Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.13.

Perspective Therapeutics Price Performance

CATX stock opened at $2.61 on Thursday. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05. The business’s 50-day simple moving average is $3.21 and its 200 day simple moving average is $7.76.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Y Intercept Hong Kong Ltd bought a new position in shares of Perspective Therapeutics in the fourth quarter valued at approximately $33,000. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics in the fourth quarter valued at approximately $34,000. National Bank of Canada FI raised its stake in shares of Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after acquiring an additional 10,998 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after acquiring an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics in the fourth quarter valued at approximately $51,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.